Figure 4.

RNLS agonist peptide RP81 protects in vitro against cisplatin-induced cytotoxicity. (A) Schematic drawing of RNLS gene showing exons (numbered), the three major isoforms, and sequences of peptides RP81 derived from exon 6, which is conserved in all splicing variants. (B) A representative WST-1 assay: mouse proximal tubular cells TKPTS were treated without (Mock) or with BSA, or RP81, or empty MNP, or RP81 encapsulated in MNP (RP81-MNP, n=9) for 24 hours, followed by 24-hour treatment with or without cisplatin. The relative cell viability is expressed as mean±SEM; n=9 for Mock, MNP, and RP81-MNP; n=3 for BSA; n=6 for RP81. *P<0.05; ****P<0.0001.